Synthesis of wiedendiol-A and wiedendiol-B from labdane diterpenes
摘要:
Two efficient enantiospecific syntheses of wiedendiol-A (1) from (-)-sclareol (7), via 11-bromo-8-drimene (11) and 8-drimen-11-al (3), are reported. The first enantiospecific synthesis of wiedendiol-B (2), via 8S,9S-driman-11-al (26), by two alternative routes starting from 7 and (+)-cis-abienol (8) is also described. 21 prepared from protocatechualdehyde (17) was used as aromatic synthon for preparing 1 and 2. (C) 1998 Published by Elsevier Science Ltd. All rights reserved.
Total Synthesis and Structure Revision of (−)-Siphonodictyal B and Its Biomimetic Conversion into (+)-Liphagal
作者:Adrian W. Markwell-Heys、Kevin K. W. Kuan、Jonathan H. George
DOI:10.1021/acs.orglett.5b01973
日期:2015.9.4
reassigned on the basis of the total synthesis of both possible C-8 epimers. The revised structure of siphonodictyal B was converted into liphagal by acid catalyzed rearrangement of a proposed epoxide intermediate. This biomimetic cascade features a succession of four distinct reactions (epoxidation, o-quinone methide formation, ringexpansion, and benzofuran formation) that occur in a one-pot operation
Enantiospecific Synthesis of Wiedendiol-B from (−)-Sclareol and (+)-cis-Abienol
作者:Alejandro F. Barrero、Enrique J. Alvarez-Manzaneda、Rachid Chahboun
DOI:10.1016/s0040-4039(97)10119-8
日期:1997.11
The first enantiospecific synthesis of the cholesteryl ester transfer protein (CETP) inhibitor wiedendiol-B (1) is described. The drimanic synthon was prepared from (-)-sclareol (4) and (+)-cis-abienol (13) by two alternative routes. The key steps of the reaction sequences are the chemo-and diastereoselective hydrogenation of the C-8-C-9 double bond of enal 6 and the stereoselective cationic hydrogenation of the hydroxyl group of 13, respectively, and the selective reduction of benzyl groups of 15. (C) 1997 Elsevier Science Ltd.
LIPHAGAL ANALOG AND MULTI-TARGETED KINASE INHIBITOR CONTAINING LIPHAGAL OR ANALOG THEREOF
申请人:TOHOKU UNIVERSITY
公开号:US20210198271A1
公开(公告)日:2021-07-01
Provided is an inhibitor for at least one kind of kinase selected from the group consisting of CDK7, CDK4, CDK6, PIM2, TSSK3, MST4, NEK6, MAP3K, MST3, DDR1, SPHK1, CaMK1, AurA, BRK, CaMK4, and PIM1, the inhibitor including as an active ingredient a compound represented by the following general formula (1) or a salt thereof: in the general formula (1), R
1
, R
2
, R
3
, R
4
, R
5
, and R
6
are as described in Description.